|
|
||||||||||
|
J Am Coll Cardiol, 2001; 38:1821-1828 © 2001 by the American College of Cardiology Foundation |








* Department of Pharmacology, Shiga University of Medical Science, Seta, Otsu, Shiga, Japan
Third Department of Medicine, Shiga University of Medical Science, Seta, Otsu, Shiga, Japan
Cardiovascular Division, Osaka Police Hospital, Kitayama-cho, Tennoji-ku Osaka, Japan
Laboratory of Biochemistry, Faculty of Horticulture, Chiba University, Matsudo, Chiba, Japan
Manuscript received May 1, 2001; revised manuscript received August 13, 2001, accepted August 29, 2001.
* Reprint requests and correspondence: Dr. Atsunori Kashiwagi, Third Department of Medicine, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan
kasiwagi{at}belle.shiga-med.ac.jp
| Abstract |
|---|
|
|
|---|
We investigated whether abnormal pteridine metabolism is related to coronary endothelial dysfunction in insulin-resistant subjects.
BACKGROUND
Depletion of tetrahydrobiopterin (BH4) and elevation of the 7,8-dihydrobiopterin (BH2) (activating and inactivating cofactors of nitric oxide synthase [NOS], respectively) contribute to impairment of NO-dependent vasodilation through reduction of NOS activity as well as increased superoxide anion generation in insulin-resistant rats.
METHODS
Thirty-six consecutive nondiabetic, normotensive and nonobese subjects with angiographically normal coronary vessels were studied. Traditional coronary risk factors, plasma pteridine levels, activities of erythrocyte dihydropteridine reductase (DHPR), the recycling enzyme that converts BH2 to BH4 and lipid peroxide (LPO) levels were measured and coronary endothelial function was assessed with graded infusions of acetylcholine (ACh).
RESULTS
When we divided patients into tertiles based on insulin sensitivity, we observed stepwise decreases in the maximal ACh-induced vasodilation and plasma BH4/7,8-BH2 ratio, and increases in coronary LPO production as insulin sensitivity decreased. The ACh-induced vasodilation was positively correlated with insulin sensitivity, BH4/7,8-BH2 ratio and DHPR activity. Furthermore, BH4/7,8-BH2 was inversely correlated with DHPR activity and insulin sensitivity. In multiple stepwise regression analysis, BH4/BH2 was independently related to ACh-induced vasodilation and accounted for 39% of the variance. However, no significant correlation existed between other traditional risk factors and BH4/7,8-BH2.
CONCLUSIONS
These results indicate that both abnormal pteridine metabolism and vascular oxidative stress are linked to coronary endothelial dysfunction in the insulin-resistant subjects.
| ||||||||||||||||||||||||||||||||||||||||||
There is increasing experimental evidence that (6R)-5,6,7,8-tetrahydrobiopterin (BH4), the natural and essential cofactor of NOS, plays a crucial role not only in increasing the rate of NO generation by NOS but also in controlling the formation of superoxide anion (O2) in endothelial cells (8). The biosynthesis of intracellular BH4 is governed by two enzymes: GTP cyclohydrolase I (GTP-CH1), which regulates its rate of formation, and dihydropteridine reductase (DHPR), which regulates its rate of regeneration. Utilization of BH4 in NO synthesis generates quinonoid dihydrobiopterin rather than dihydrobiopterin (BH2) (8,9). Alternatively, quinonoid BH2 may rearrange nonenzymatically to BH2, which is no longer a substrate for DHPR (10). To maintain BH4, increases in both enzyme activities are crucial. We have recently reported that under insulin-resistant conditions where the BH4 levels are in a subnormal range, the excessive production of O2 by NO synthase may lead to hydroxyl radical production and oxidative tissue damage (11). This hypothesis was supported by the finding that long-term activation of endothelial NOS (eNOS) by oral administration of BH4 prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats (12).
Therefore, we examined the effect of insulin resistance on in vivo pteridine metabolism and endothelial dysfunction, which we evaluated by analyzing graded degrees of ACh-induced vasoconstriction in subjects with angiographically normal coronary arteries.
| Methods |
|---|
|
|
|---|
Baseline investigation. One day before cardiac catheterization, venous blood samples were drawn from each subject after an overnight fast for measurements of plasma glucose, insulin, total cholesterol, triglyceride and high-density lipoprotein cholesterol. A 75-g load of oral glucose (Trelan G 75, Shimizu, Shizuoka) was administered, and blood samples were drawn at 30, 60 and 120 min for determination of plasma glucose and insulin concentrations. Plasma glucose and insulin responses to glucose ingestion were evaluated by calculation of the areas under the curves of glucose and insulin throughout the 120 min of the test period. The definition of glucose tolerance was based on a 2-h oral glucose tolerance test (OGTT) according to the criteria of the American Diabetes Association (16). Hypertension was defined as systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg. As a cumulative estimate of tobacco consumption, cigarette-years (pieces/day x years) was used.
Coronary angiography.
Coronary angiography was performed by the Judkins technique using a biplane cineangiography system in the morning when the patients were fasting (17). Thirty subjects (83.3%) had completely normal coronary arteries, and those of the others were nearly normal (<25% stenosis). Incremental doses of ACh (50 µg, 100 µg) were injected into the left main coronary artery through the catheter. Coronary spasm was defined as total or subtotal (a change in diameter
75%) vessel occlusion associated with chest pain or ischemic ST changes on the electrocardiogram or both. After the completion of the intracoronary injection of ACh, when the systemic hemodynamic parameters and the coronary arterial diameter on angiograms had returned to the baseline levels, 300 µg of nitroglycerin (NTG) was injected into the coronary artery, and coronary angiography was performed in multiple projections. The luminal diameter at the center of the left anterior descending artery was measured quantitatively with the use of a computer-assisted coronary angiographic analysis system (GE Medical Systems, Milwaukee, Wisconsin) by two observers blinded to the clinical history and risk-factor profile (18). Responses of coronary artery diameter to infusion of ACh and NTG were expressed as percentage changes from the baseline coronary diameter (i.e., 100 x [diameter after ACh or NTG baseline diameter]/baseline diameter).
Blood sampling.
Blood samples were collected simultaneously from the coronary sinus (CS) and descending aorta (Ao) 1 min before and 1 min after ACh injection at the same speed and were placed on ice immediately after collection. A 10-ml blood sample was drawn into an ethylenediamine tetraacetate vacutainer and centrifuged at 3,000 rpm for 15 min at 4°C. After plasma was separated and the buffy coat was removed, erythrocytes were suspended in phosphate-buffered saline and centrifuged again. Thus, obtained packed erythrocytes and the separated plasma were stored at 80°C until use. Coronary lipid peroxide (LPO) production during ACh infusion was calculated by the formula:
Plasma concentrations of biopterin derivative and total radical-trapping antioxidant parameter (TRAP) and erythrocyte DHPR activity were not significantly different between the CS and Ao regardless of ACh injection. Therefore, the levels of these variables were measured in the samples collected from the CS before ACh injection.
Plasma biopterin derivative levels and DHPR activities. Plasma biopterin levels were measured by high-performance liquid chromatography as previously described (11,12). The amount of BH4 was estimated from the difference between the total (BH4 + 7,8-BH2 + oxidized biopterin) and alkaline-stable biopterin (7,8-BH2 + oxidized biopterin). The DHPR, the recycling enzyme to convert BH2 to BH4, was assayed by the method of Arai et al. (19).
Measurement of LPO content and TRAP. Plasma TBARS content was measured by the fluorometric method described previously (20). Plasma antioxidant defenses were evaluated by measuring the TRAP (21).
Statistical analysis. All values are presented as means ± SE. All analyses were performed using a personal computer with the statistical software package SPSS, version 6.0. Group differences of categorical data were tested by chi-square analysis with the Yates correction. The plasma glucose and insulin responses in the three groups during OGTT, blood pressure and lipid concentrations were compared using analysis of variance with a post hoc Scheffé comparison. The dose-dependent vascular responses were compared among the three groups using repeated-measures analysis of variance. The Pearson coefficient was used for normally distributed data, and the Spearman coefficient was used for abnormally distributed data to assess the relation between continuous factors. A p value < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
800 pmol/l x h, 12 as insulin sensitive (IS) with 2-h insulin area
600 pmol/l x h, and 12 as borderline (BL) with 2-h insulin area over 600 and <800 pmol/l x h. As shown in Table 1, subjects in the three groups were comparable with regard to age, gender, body-mass index, proportions of glucose tolerance and blood pressure. Both the percentage of active smokers and cumulative tobacco consumption were significantly higher in the IR than in the IS group. Analysis of the data from the OGTT showed that both fasting glucose level and 2-h glucose area were not significantly different among IS, IR and BL subjects, whereas the IR group had higher fasting insulin values than the other groups. There were no significant differences in plasma total cholesterol and HDL cholesterol among these three groups despite higher triglyceride concentration in IR subjects than in the other groups.
|
|
|
Lipid peroxidation and antioxidant system components. The increase in the plasma levels of TBARS above the basal value after ACh injection was slightly but not significantly higher in IR subjects than in the other groups (IS, 2.30 ± 0.59; BL, 2.24 ± 0.46; IR, 3.13 ± 0.38 nmol/ml). In contrast, there was a trend toward decreased plasma levels of TRAP as insulin sensitivity decreased, and the TRAP level in IR subjects was significantly lower than that in IS subjects (IS, 303 ± 39; BL, 247 ± 27; IR, 197 ± 32 µmol/l, p < 0.05).
Analyses of risk factors for endothelial dysfunction. Univariate analysis showed that the constrictor response of the coronary diameter to ACh (100 µg) had a significant positive correlation with the 2-h insulin area, TBARS level (Fig. 2) and cigarette-years (r = 0.36, p < 0.05). Conversely, an inverse correlation between the response to ACh and either BH4/7,8-BH2 ratio or DHPR activity was observed. To exclude the possibility that angiographic results in the spasm patients might affect the results of the present study, these univariate analyses were carried out in subjects without vasospasm. As a result, a similar tendency was observed in these subjects. A 2-h insulin area as a marker of insulin resistance was positively correlated with 7,8-BH2 plus biopterin and TBARS level, and this was inversely correlated with BH4/7,8-BH2 ratio, BH4/total biopterin and DHPR activity. Interestingly, lower BH4/7,8-BH2 ratio was correlated with higher cumulative tobacco consumption. Similarly, DHPR activity was associated with an increase in BH4/7,8-BH2 ratio, and a decrease in TBARS level.
|
|
| Discussion |
|---|
|
|
|---|
Insulin resistance and vascular oxidative stress. Several lines of evidence now link excess vascular oxidative stress to the impairment of NO action in subjects with insulin resistance (2,5). We have previously reported that insulin resistance causes oxidative stress to cardiovascular tissues and the release of oxygen free radicals from endothelial cells (11). Moreover, not only was there an increase in the LPO level, but also marked activation of redox-sensitive transcription factors in cardiovascular tissues of insulin-resistant rats (12). In separate analyses, plasma levels of TBARS were also significantly increased in patients with VSAP compared with control subjects (control, 1.70 ± 0.29; VSAP, 3.34 ± 0.53 nmol/ml, p < 0.05). These findings suggest that increased oxidative stress associated with insulin resistance contributes to endothelial dysfunction in patients with VSAP.
Pteridine metabolism and eNOS activity. Previous data from our laboratory and other groups suggest abnormal pteridine metabolism as a possible mechanism linking insulin resistance to vascular disease (11,12). In vivo data suggest that increased plasma BH4 levels can augment endothelial NO production (22). Endothelial cells constitutively release substantial amounts of BH4 and neopterin (23). Neopterin is an oxidized product of 7,8-dihydroneopterin-triphosphate, the intermediate generated by GTP-CH1. The constancy of the neopterin to biopterin ratio and total biopterin levels (Table 2) suggest that the activity of GTP-CH1 is not decreased in the insulin-resistant state. These results suggest that reduction in the BH4/7,8-BH2 ratio rather than depletion of BH4 is associated with impaired eNOS activity and thereby contributes to the defective ACh-induced vasodilation observed in human insulin-resistant states. The plasma 7,8-BH2 levels in IR subjects showed highly significant increases, suggesting that the insulin-resistant state leads to increases in the synthesis of BH2.
As illustrated in Figure 3, because BH4 is rapidly oxidized to 7,8-BH2, a lack of sufficient DHPR activity would lead to accumulation of 7,8-BH2, which has been shown to inhibit the stimulatory effects of BH4 on NO synthase (24). In addition, high concentrations of 7,8-BH2 inhibit GTP-CH1 and hence de novo synthesis of BH4 (9). Therefore, although it remains uncertain to what extent endothelial cells are responsible for and/or are affected by these declines, the present results support the hypothesis that insulin resistance induces vascular dysfunction through alterations in the BH4/7,8-BH2 ratio (14).
|
In the present study, DHPR activity was correlated with the BH4/7,8-BH2 ratio. Interestingly, it has been reported that physiological concentrations of glutathione increase the synthesis and biological activity of NOS by activating DHPR (26). Consistent with these results, administration of either GSH or vitamin C improves the impairment of endothelium-dependent vasodilation in patients with coronary spastic angina (5,6). Although the multivariate analysis was negative for cigarette smoking, higher cumulative tobacco consumption was correlated with lower BH4/7,8-BH2 ratio and the maximal ACh-induced vasoconstriction. Therefore, a high frequency of smokers among IR subjects would be an explanation for decreased DHPR activity and BH4/7,8-BH2 ratio. In this context, it is conceivable that the abnormal intracellular redox state in the insulin-resistant state, which is unfavorable for reduction of the oxidized biopterin, impairs the endothelial recycling of BH4, and an optimal ratio of BH4/7,8-BH2 is critical for eNOS activation.
Clinical usefulness and limitations of biopterin derivatives as markers for vascular function. The interpretation of changes in plasma and tissue biopterin derivative levels as reflections of tissue contents of those derivatives remains speculative in the present study. However, it has been shown that when DHPR activity is decreased, more 7,8-BH2 appears in the plasma, and the plasma 7,8-BH2 is low when de novo synthesis of BH4 is low (27). Furthermore, we have also reported that plasma and tissue biopterin levels are closely associated with each other (12). These results suggest that measurement of pteridines would provide a sensitive and informative measure of changes in the function of vascular cells. Moreover, the hypothesis that patients with abnormal pteridine metabolism are at increased risk of developing cardiovascular disease, including high blood pressure, VSAP, and atherosclerosis, must be further investigated.
Conclusions. Finally, the novel observation of this study is that deranged endothelial responses to ACh in the insulin-resistant state are, at least in part, due to impairments of the NO system caused by abnormal pteridine metabolism and vascular oxidative stress.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. Antoniades, C. Shirodaria, T. Van Assche, C. Cunnington, I. Tegeder, J. Lotsch, T. J. Guzik, P. Leeson, J. Diesch, D. Tousoulis, et al. GCH1 Haplotype Determines Vascular and Plasma Biopterin Availability in Coronary Artery Disease: Effects on Vascular Superoxide Production and Endothelial Function J. Am. Coll. Cardiol., July 8, 2008; 52(2): 158 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Rao, L. Zhang, and D. T. O'Connor Complex Trait Genetics: The Role of Mechanistic "Intermediate Phenotypes" and Candidate Genetic Loci J. Am. Coll. Cardiol., July 8, 2008; 52(2): 166 - 168. [Full Text] [PDF] |
||||
![]() |
T. Ashikaga, M. Nishizaki, H. Fujii, K. Ihara, S. Niki, T. Murai, S. Maeda, N. Yamawake, Y. Kishi, and M. Isobe Coronary Endothelial Dysfunction and Impaired Microcirculation Response to Atrial Natriuretic Peptide in Hyperinsulinemia Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 58 - 63. [Abstract] [PDF] |
||||
![]() |
C. Antoniades, C. Shirodaria, M. Crabtree, R. Rinze, N. Alp, C. Cunnington, J. Diesch, D. Tousoulis, C. Stefanadis, P. Leeson, et al. Altered Plasma Versus Vascular Biopterins in Human Atherosclerosis Reveal Relationships Between Endothelial Nitric Oxide Synthase Coupling, Endothelial Function, and Inflammation Circulation, December 11, 2007; 116(24): 2851 - 2859. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Reddy, Y. Hao, S.-H. Lee, S. R. Gangireddy, C. Owyang, and M. J. DiMagno Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders? Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G112 - G120. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Moens and D. A. Kass Tetrahydrobiopterin and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2439 - 2444. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Erdos, J. A. Snipes, C. D. Tulbert, P. Katakam, A. W. Miller, and D. W. Busija Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1264 - H1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Chander, O. Gealekman, S. V. Brodsky, S. Elitok, A. Tojo, M. Crabtree, S. S. Gross, and M. S. Goligorsky Nephropathy in Zucker Diabetic Fat Rat Is Associated with Oxidative and Nitrosative Stress: Prevention by Chronic Therapy with a Peroxynitrite Scavenger Ebselen J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2391 - 2403. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kawashima and M. Yokoyama Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 998 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Erdos, J. A. Snipes, A. W. Miller, and D. W. Busija Cerebrovascular Dysfunction in Zucker Obese Rats Is Mediated by Oxidative Stress and Protein Kinase C Diabetes, May 1, 2004; 53(5): 1352 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Erdos, S. A. Simandle, J. A. Snipes, A. W. Miller, and D. W. Busija Potassium Channel Dysfunction in Cerebral Arteries of Insulin-Resistant Rats Is Mediated by Reactive Oxygen Species Stroke, April 1, 2004; 35(4): 964 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Werner, A. C.F. Gorren, R. Heller, G. Werner-Felmayer, and B. Mayer Tetrahydrobiopterin and Nitric Oxide: Mechanistic and Pharmacological Aspects Experimental Biology and Medicine, December 1, 2003; 228(11): 1291 - 1302. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ihlemann, C. Rask-Madsen, A. Perner, H. Dominguez, T. Hermann, L. Kober, and C. Torp-Pedersen Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H875 - H882. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G Harrison, Hua Cai, U. Landmesser, and K. K Griendling The Pickering Lecture British Hypertension Society, 10th September 2002: Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 51 - 61. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |